Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2010

View Archived Issues

Merck & Co.'s new GPR119 agonist lowers blood glucose in murine diabetes model

Angiochem's EPiC platform yields anticancer drugs with improved brain penetration

Renovis identifies novel P2X3 and P2X2/3 receptor antagonists

Janssen discloses novel NOP (ORL1) opioid receptor modulators

University of Central Florida claims new STAT3 inhibitors

Novartis presents novel antibacterial agents

Institute for OneWorld Health claims novel CFTR inhibitors

AD5-10: new option for treatment of ovarian cancer

Celgene and Agios collaborate to develop cancer metabolism programs

Advaxis begins phase II trial of ADXS11-001 in cervical dysplasia

Impax completes enrollment in phase III IPX-066 trial in Parkinson's disease

Genocea and U.S. military to collaborate on development of malaria vaccine

Mirabegron well tolerated and improves overactive bladder variables in large study

Studies on progesterone caproate for prevention of preterm birth

Rexahn reports phase IIa Serdaxin data in major depressive disorder

Impax amends copromotion agreement with Wyeth

D-Pharm receives agreement letter on SPA for phase III DP-b99 trial in acute ischemic stroke

Alexion's Soliris approved in Japan for paroxysmal nocturnal hemoglobinuria

PhytoMedical signs letter of intent with Medicilon for studies on brain cancer drug candidate

Updated phase I data presented on JI-101 in solid tumors

Diquas ophthalmic solution approved in Japan for dry eye treatment

Sandoz to acquire Oriel Therapeutics

Cell Therapeutics nears MAA submission for pixantrone in E.U.

FDA approves Tarceva as maintenance therapy for advanced non-small cell lung cancer

Cannasat Therapeutics becomes Cynapsus Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...